The mechanisms by which tumor microenvironments modulate nucleic acid–mediated
innate immunity remain unknown. Here we identify the receptor TIM-3 as key in …

The characteristics of the tumor microenvironment vary widely. New work shows that after
tumor-associated expression of the receptor TIM-3 by dendritic cells, TIM-3 inhibits the …

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a
molecule expressed on interferon-γ producing T cells, is emerging as an important immune …

Dendritic cells (DCs) sense environmental cues and adopt either an immune-stimulatory or
regulatory phenotype, thereby fine-tuning immune responses. Identifying endogenous …

Blockade of the inhibitory receptor TIM-3 shows efficacy in cancer immunotherapy clinical
trials. TIM-3 inhibits production of the chemokine CXCL9 by XCR1+ classical dendritic cells …

Acquisition of cell-associated tumor antigens by type 1 dendritic cells (cDC1) is essential to
induce and sustain tumor specific CD8+ T cells via cross-presentation. Here we show that …

The STING and absent in melanoma 2 (AIM2) pathways are activated by the presence of
cytosolic DNA, and STING agonists enhance immunotherapeutic responses. Here, we show …

T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) negatively regulates
innate and adaptive immunity in cancer. To identify the mechanisms of Tim-3 in cancer …

The role of B cells in anti-tumour immunity is still debated and, accordingly,
immunotherapies have focused on targeting T and natural killer cells to inhibit tumour …

Intratumoral CD103+ dendritic cells (DCs) are necessary for anti-tumor immunity. Here we
evaluated the expression of immune regulators by CD103+ DCs in a murine model of breast …